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Abstract
Background: According to mRNA microarray, proteomics and other studies, biological abnormalities of eutopic
endometrium (EM) are involved in the pathogenesis of endometriosis, but the relationship between mRNA and
protein expression in EM is not clear. We tested for the first time the hypothesis that EM TRIzol extraction allows
proteomic Surface Enhanced Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (SELDI-TOF MS) analysis
and that these proteomic data can be related to mRNA (microarray) data obtained from the same EM sample from
women with and without endometriosis.
Methods: Proteomic analysis was performed using SELDI-TOF-MS of TRIzol-extracted EM obtained during secretory
phase from patients without endometriosis (n = 6), patients with minimal-mild (n = 5) and with moderate-severe
endometriosis (n = 5), classified according to the system of the American Society of Reproductive Medicine.
Proteomic data were compared to mRNA microarray data obtained from the same EM samples.
Results: In our SELDI-TOF MS study 32 peaks were differentially expressed in endometrium of all women with
endometriosis (stages I-IV) compared with all controls during the secretory phase. Comparison of proteomic results
with those from microarray revealed no corresponding genes/proteins.
Conclusion: TRIzol treatment of secretory phase EM allows combined proteomic and mRNA microarray analysis of
the same sample, but comparison between proteomic and microarray data was not evident, probably due to post-
translational modifications.
Background
Endometriosis is a gynaecological disorder, defined as
t h ep r e s e n c eo fe n d o m e t r i a l -like tissue outside the
uterus and is associated with chronic intrapelvic inflam-
mation. Its symptoms can impact on general well-being
[1] and include severe dysmenorrhoea; deep dyspareu-
nia; chronic pelvic pain; cyclical or premenstrual symp-
toms (e.g. bowel or bladder associated) with or without
abnormal bleeding; infertility and chronic fatigue.
Well established biological differences between eutopic
endometrium from women with and without endome-
triosis represent an interesting scientific basis to develop
a semi-invasive diagnostic test for endometriosis based
on these differences. Recent evidence suggests that sig-
nificant biological differences between eutopic endome-
trium from women with and without endometriosis [2]
may offer the basis for a semi-invasive diagnostic test
based on the analysis of an endometrial biopsy. Numer-
ous proteomic [3-10] and mRNA microarray [11-14]
studies have demonstrated important biological differ-
ences between eutopic endometrium from women with
and without endometriosis. Furthermore, data from
other investigators [15-17] and from our group [18]
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the increased endometrial density of nerve fibres in
women with endometriosis compared to controls.
The primary aim of this study was to test the hypoth-
esis that TRIzol extraction of endometrium enables a
combined mRNA microarray and proteomic analysis of
the same EM sample from both women with and with-
out endometriosis. The secondary aim of our study was
to compare proteomic data (presented in this study)
with mRNA microarray data [13] of the same EM
sample.
Methods
Patient selection
The same endometrium samples selected for this study
were as those used in our previous microarray study
[13]. Briefly, the biobank of the Leuven University Ferti-
lity Centre was searched to identify 16 endometrial
(EM) samples obtained during the secretory phase
(dated between day 23 - 26) from each of the following
3 groups, women with a normal pelvis (controls, n = 6),
women with minimal to mild endometriosis (stages I-II,
n = 5), and from women with moderate to severe endo-
metriosis (stages III-IV, n= 5). Endometriosis was staged
according to the classification system of the American
Society of Reproductive Medicine [19]. Endometrial
samples had been collected during hysteroscopy/laparo-
scopy procedures for either infertility or pain and had
been frozen at -80°C until use. None of our patients
took oral contraceptives or other hormonal treatment
for endometriosis within 3 months prior to EM sample
collection. Women with and without endometriosis had
the following age (mean 28.10±2,767, median 27.5,
range 26-29.5 years) and (mean 32.33±3.933, median 33,
range 28.50-35.5 years), respectively. All patients had
signed a written informed consent before surgery and
had agreed on the collection of tissues for research. The
study protocol had been approved by the institutional
ethical and review board of the University Hospital
Gasthuisberg for the protection of human subjects.
Preparation of endometrial samples
TRIzol (Invitrogen Life Technologies, Carlsbad CA,
USA) [20], a monophasic solution of phenol and guani-
dine isothiocyanate, was used as a one step reagent for
the extraction of RNA, Protein from each EM sample.
The protein quantity and quality was analyzed on the
Nanodrop and protein measurements ranged between
0,39 to 16 mg/ml. 10 μg of protein concentration were
used to spot on each surface.
Frozen EM tissue biopsies were immediately thawed in
TRIzol reagent according to the instructions of the
manufacturers. Briefly, tissues were homogenized using
a glass tube with a glass stick to smash the sample to
pieces, 300 μl/105 μl chloroform were added and left at
room temperature for five minutes. The samples were
c e n t r i f u g e da t1 00 0 0r p ma t4 ° Cf o r1 5m i n u t e s .T h e
upper aqueous phase was separated and washed with
Qiagen kit (following manufacturer’s instructions). The
aliquot including the protein fraction were thawed on
ice and sonicated. 600 μl acetone was added with inver-
sion and left at room temperature for 10 min. The sam-
p l e sw e r ec e n t r i f u g e da t1 2 0 0 0r p ma t4 ° Cf o r1 0
minutes. Twice 0.5 ml of 0.3 M urea in 95% ethanol
was added and left at room temperature for 10 min.
The samples were centrifuged at 8,000 g for 5 minutes
and twice 1 ml of urea/ethanol were added and dis-
solved in 300 μl U9 Ciphergen (9 M Urea, 2% 3-[(3-cho-
lamidopropyl) dimethyl-ammonio]-1-propanesulfonate
(CHAPS), 50 mM tris(hydroxymethyl)aminomethane-
HCl (Tris-HCl) pH 9.0) (Ciphergen Biosystems, Fre-
mont, CA, USA). The samples were sonicated and left
at room temperature for 10-20 minutes and spun at
8,000 g for 5 minutes to sediment the insoluble protein.
The samples were stored at -80°C.
ProteinChip Arrays
First a brief test phase was performed on four chip types
(Cm10, IMAC30-Cu, H50 and Q10) to find the best
(rich spectra) chip type for this experiment. Two differ-
ent chip surfaces with distinct chromatographic proper-
ties and binding affinities were used, Weak cation
exchange surface (CM10) with a low stringency binding
buffer (50 mM NaOAC, pH 4.0) and Immobilized
metallic affinity capture surface (IMAC-30-Cu) loaded
with CuSO4, with a 0.1 M phosphate, 0.5 M NaCl,
pH7.0.
Briefly, ProteinChip array spots were equilibrated
with 150 μl of respective binding buffer (Ciphergen,
Fremont, CA, USA) while shaking twice for five min-
utes at room temperature to pre-activate binding sur-
faces. Then, 20 μlo fs a m p l e( 1 0μgp e rs p o t )d i l u t e d
(1:5 vol/vol) with the surface-type dependent binding
buffer were loaded onto each spot in duplicate and
incubated for 60 minutes at room temperature while
being shaken in the dark (MicroMix5, form 20, ampli-
tude 5; Diagnostics Product Corporation, Gwynedd,
Wales, United Kingdom). The unbound proteins/pep-
tides on the ProteinChip array surfaces were washed
away with appropriate buffer twice for 5 minutes
rinsed in 150 μl of Milli-Q water and air-dried. Mass
spectra of the retained proteins were obtained by
ionising the proteins using two types of energy absorb-
ing molecules (EAM): alpha-cyano-4-hydroxy cinnamic
acid (CHCA), for small molecules (< 15 kDa), and
sinapinic acid (SPA), for larger molecules (both EAM
were obtained from Ciphergen, Fremont, CA, USA).
The CHCA (5 mg CHCA dissolved in 150 μlo f5 0 %
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Page 2 of 6acetonitrile, 0.5% trifluoroacetic acid) was diluted five
times in the respective solvent, and 1 μl was applied
twice onto the retained proteins on the spots. The
SPA (5 mg SPA dissolved in 400 μl of 50% acetoni-
trile, 0.5% trifluoroacetic acid) was applied in two con-
secutive steps in volumes of 1 μl. Analysis of the
retained proteins was performed with a Protein Biolo-
gical System-IIC (PBSIIC) linear SELDI-TOF-MS
instrument (Ciphergen). Mass accuracy was calibrated
externally with the all-in-one peptide molecular mass
standard (Ciphergen Biosystems, Fremont, CA, USA)
for the mass range of 1.6 kDa-20 kDa and with the
all-in-one protein molecular mass standard (Ciphergen
Biosystems, Fremont, CA, USA) for the mass range of
8-150 kDa.
Statistical analysis of proteomic data
The SELDI-TOF mass spectra were baseline corrected
and normalised on the basis of total ion current using
the Biomarker Wizard Program (Ciphergen, Fremont,
CA, USA). The same application was used for peak
detection and the determination of p-values. All univari-
ate analyses were carried out using Ciphergen’sP r o -
teinChip Software v3.1.1 (Ciphergen, Fremont, CA,
USA) and the Prism 5 software (GraphPad, San Diego,
CA, USA). Results are expressed as mean.
Comparison of proteomics and microarray data
The endometrium samples of the mRNA microarray
study which were used in this study revealed that 9
genes were differentially expressed in women with and
without endometriosis. The molecular weights of these
9 representative proteins [13] were identified using a
search via [21] and are shown in Table 1.
Results/Discussion
In this study, we showed for the first time that com-
bined analysis of one endometrial sample from women
with and without endometriosis for both mRNA (Micro-
array) and protein fraction (SELDI-TOF MS) is possible
after TRIzol extraction. Although we were able to com-
pare these endometrial samples with respect to mRNA
protein expression (microarray, [13]) and protein
expression (proteomics, presented in this study), no cor-
responding proteins/genes were found.
In our mRNA microarray study [13] 8 genes were up-
regulated and one gene was down-regulated in eutopic
endometrium of women with endometriosis compared
to controls. Real-time PCR analysis of protocadherin-17
(PCDH17), protein tyrosine phosphatase, receptor type,
R (PTPRR) and interleukin-6 signal transducer (IL6ST)
expression validated the microarray findings [Table 1;
[13]]. In our SELDI-TOF MS study 32 peaks were dif-
ferentially expressed in endometrium of all women with
endometriosis (stages I-IV) compared with all controls
during the secretory phase [Table 2]. The proteins of
interest detected by SELDI-TOF MS had a lower range
(5-32 kDa) than the 9 genes detected by mRNA (repre-
sentative protein range 33-272 kDa, [13]) with the
exception of Synuclein, gamma which has a range of
molecular weight of 13 kDa. This observation can be
explained by the fact that protein activity often depends
on post-translational modifications, which are not pre-
dictable from the level of the corresponding transcript
[22], and confirm recent data [7] that eutopic endome-
trial protein expression, analyzed by 2D-differential in
gel electrophoresis (DIGE) and mass spectrometry, does
not correlate well with published gene array data.
Although it is not clear why different mass peaks were
observed in results comparing moderate-severe endome-
triosis (25 peaks) versus controls as opposed to results
comparing minimal-mild endometriosis (23 peaks) ver-
sus controls [Table 3 and 4], it is possible that specific
peptides or proteins are associated with specific stages
of the disease. It is also not clear why the proteomic
Table 1 The representative molecular weights of the
proteins identified in the mRNA Microarray study [13]
Protein Mass in Da
Osteoglycin (OGN/4969) 33,922
Interleukin-6 signal transducer (IL6ST/3572) isoform 1. 103,537
isoform 2. 37,499
Cytochrome P450, Family 2, Subfamily J,
polypeptide 2 (CYP2J2/1573)
57,611
Carboxypeptidase E (CPE/1363) 53,151
Fibronectin 1 (FN1/2335) different isoforms
1. 262,607
2. 71,943
3. 259,198
4. 222,944
5. 243,316
6. 240,477
7. 268,894
8. 252,793
9. 246,670
10. 239,608
11. 262,388
12. 221,274
13. 249,304
14. 249,384
15. 272,302
Synuclein, gamma (SNCG/6623) 13,331
BAI1-associated protein 2 (BAIAP2/10458) different isoforms
1. 60,868
2. 59,014
3. 56,626
4. 57,359
5. 57,445
6. 57,430
Protocadherin 17 (PCDH17/27253) different isoforms
1. 126,229
2. 96,570
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[5,6] were not confirmed in the present study. In our
first pilot study, [6] SELDI-TOF MS profiling of EM
samples showed that the expression of proteins and
peptides in the range of 2.8 -12.3 kDa was 3-24 times
lower in endometrium of women with endometriosis
compared with in women without endometriosis. In our
second study [5], the combination of SELDI-TOF MS
ProteinChip technology with bioinformatics allowed us
to develop a diagnostic test for minimal-mild endome-
triosis based on a panel of 4 mass peaks (2 up-regulated:
90.675 kDa and 35.956 kDa and 2 down-regulated: 1.9
kDa and 2.5 kDa) with maximal sensitivity (100%) and
specificity (100%). We hypothesize that various factors
may contribute to this lack of confirmation. Firstly, the
protein extraction method was based on TRIzol (Invitro-
gen Life Technologies, Carlsbad CA, USA) in the cur-
rent study and on U9 lysis buffer (Ciphergen
Biosystems, Fremont, CA) in our previous studies [5,6].
Secondly, endometrial biological changes related to the
menstrual cycle [23] may lead to differential protein
expression in EM samples obtained on day 23-26 of
the cycle (current study), compared to EM samples
obtained during secretory phase (day 20-22) or
Table 2 Mean signal intensities of various proteins and
peptides comparing endometrium of women with a
normal pelvis versus endometriosis (CM10 and IMAC)
CM10
CHCA
M/z pvalue Mean Disease Mean Control Up/down
14653,82 0,034 0,795 1,468 down
16851,18 0,020 0,378 0,660 down
SPAhigh
8776,32 0,020 0,854 0,310 up
8898,40 0,045 4,530 1,935 up
10115,90 0,034 7,442 3,545 up
12186,64 0,026 0,300 0,132 up
12379,95 0,011 2,028 0,420 up
12683,46 0,026 0,988 0,444 up
13464,70 0,045 0,361 0,198 up
14479,03 0,011 0,282 0,116 up
17258,59 0,034 0,370 0,168 up
SPAlow
7662,79 0,045 0,247 0,362 down
8949,82 0,026 1,310 0,720 up
9177,29 0,020 0,391 1,381 down
9941,98 0,026 2,221 1,234 up
10084,76 0,045 1,807 1,096 up
11477,23 0,034 0,087 0,167 down
12323,14 0,011 0,652 0,215 up
12623,72 0,045 0,375 0,219 up
IMAC
CHCA
M/z pvalue Mean Disease Mean Control Up/down
6299,93 0,011 0,319 0,470 down
9213,51 0,008 0,607 1,578 down
9266,22 0,011 0,933 1,440 down
9766,19 0,034 0,699 0,360 up
11163,87 0,020 0,527 0,245 up
11322,71 0,015 1,017 0,294 up
15446,04 0,004 0,586 0,108 up
SPAhigh
9532,42 0,026 3,217 13,993 down
9767,55 0,045 2,180 4,258 down
SPAlow
7832,06 0,020 0,205 0,369 down
8228,62 0,004 0,389 0,198 up
9190,05 0,015 0,420 1,406 down
9262,94 0,034 0,900 0,502 up
Table 3 Mean signal intensities of various proteins and
peptides comparing endometrium of women with a
normal pelvis versus stage I-II endometriosis (CM10 and
IMAC)
CM10
SPAhigh
M/z pvalue Mean Disease Mean Control Up/down
8898,40 0,036 4,475 1,935 up
10115,90 0,036 8,002 3,545 up
11656,79 0,036 6,899 2,721 up
11861,80 0,008 3,013 1,160 up
12186,64 0,014 0,386 0,132 up
12379,95 0,008 1,580 0,420 up
12847,34 0,023 0,668 0,228 up
13464,70 0,036 0,432 0,198 up
14659,37 0,023 2,197 1,049 up
SPAlow
7662,79 0,036 0,190 0,362 down
8078,54 0,022 0,118 0,339 down
8949,82 0,008 1,326 0,720 up
9941,98 0,008 2,382 1,234 up
10084,76 0,022 1,900 1,096 up
11801,42 0,014 0,875 0,432 up
11835,69 0,008 0,507 0,284 up
12323,14 0,008 0,727 0,215 up
15199,86 0,014 0,010 0,088 down
IMAC
CHCA
M/z pvalue Mean Disease Mean Control Up/down
11163,87 0,022 0,469 0,245 up
11322,71 0,008 0,836 0,294 up
13815,44 0,014 3,281 1,411 up
15446,04 0,036 0,283 0,108 up
SPAlow
8228,62 0,014 0,429 0,198 up
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Page 4 of 6secretory phase (day 16 - 26) in our previous studies
[5,6]. Indeed, EM histology on cycle days 23-26 is
marked by decreasing secretion, decreasing stromal
edema, increasing pseudodecidual reaction, stromal
mitoses, and leucocytic infiltration, whereas endome-
trial secretion on cycle days 18-22 is maximal with a
low proportion of stromal mitoses, and absence of
pseudodecidual reaction or leucocytic infiltration [23].
Furthermore, endometrial mRNA expression has also
been reported to be affected differently during different
phases of the cycle [24]. Thirdly, it has to be acknowl-
edged that proteomic techniques like SELDI-TOF MS
still require standardization on the level of intra- and
interassay variability. Therefore, we plan to repeat this
study in a larger sample size including well defined
endometrial samples obtained during menstrual, folli-
cular and secretory phase, to validate the reproducibil-
ity of SELDI-TOF MS technology in these samples and
to identify the protein peaks observed after proteomic
analysis, which are expensive and labour intense
requiring High-performance liquid chromatography or
high-pressure liquid chromatography (HPLC) and
matrix assisted laser desorption ionization Time-of-
Flight-Mass Spectrometry (MALDI-TOF MS).
Conclusion
TRIzol treatment of secretory phase EM allowed both
proteomic (SELDI-TOF MS) and mRNA microarray
analysis of the same sample, but comparison of protein
and mRNA expression in the same sample was not evi-
dent, probably due to post-translational modifications
and/or technical aspects.
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